ARTICLE
13 November 2023

One Too Many Suits Against FDA?

AV
Axinn Veltrop & Harkrider

Contributor

Incisive. Inclusive. Invested. We’re Axinn.

Experienced, tenacious, and always trial-ready, we are committed to understanding complex legal challenges that impact the future of our clients’ businesses, globally.

Focusing on antitrust, intellectual property, and high-stakes litigation, our extensive teams in the U.S. possess deep knowledge and client-side experience across a range of sectors, including technology, healthcare, life sciences, and consumer products.

With a strong culture of diversity, equity, and inclusion, we build relationships with our clients and colleagues alike, helping communities and acting with purpose. Our client service, entrepreneurialism, and inquisitive nature sit at the heart of the firm, enabling us to prioritize client goals and achieve successful outcomes.

Before filing a lawsuit against FDA, I often get asked by clients whether FDA will retaliate by, for example, delaying review times or more closely scrutinizing applications.
United States Food, Drugs, Healthcare, Life Sciences

Before filing a lawsuit against FDA, I often get asked by clients whether FDA will retaliate by, for example, delaying review times or more closely scrutinizing applications. My response to this question is always the same – no. FDA understands that its decisions are complicated and important. And, as long as you are not making frivolous arguments and litigate in a professional manner, FDA will respond professionally and will not hold the lawsuit against you. In fact, despite suing FDA on multiple occasions, I have always maintained a good and professional relationship with FDA and have never experienced any animosity.

But, is there a limit to FDA's tolerance for being sued? Maybe. Mihael Polymeropoulos, CEO and co-founder of Vanda Pharmaceuticals, certainly thinks so. In fact, in a recent interview, he stated that he believed that FDA was in fact retaliating against Vanda and treating it differently as a result of the multiple lawsuits that Vanda has filed against FDA.

If you have been keeping score at home, it would be an understatement to say that Vanda has been very active in filing lawsuits against FDA the last few years. Vanda stands out as perhaps being the most aggressive company in recent memory, filing separate suits challenging, among other issues, FDA's partial clinical hold on human testing for one product, a denial of a fast track designation, and a failure to schedule a hearing relating to an unapproved ANDA. Vanda has launched two separate suits challenging FDA's ANDA approval decisions – one of which challenges FDA's failure to require a generic label to have braille labeling and another that challenges FDA's bioequivalence finding. Vanda has even filed multiple lawsuits to require FDA compliance with FOIA requests.

Is FDA actively retaliating against Vanda in response to these lawsuits? That remains to be seen. But, in the meantime, my advice to companies considering a lawsuit to challenge an improper FDA decision will remain the same.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More